Poor Blood Flow to the Brain May Steer Early Tau Pathology Toward Vulnerable Regions

Reduced blood flow to the brain has long been observed in people with Alzheimer’s disease, but a persistent question has remained: does the diminished circulation merely accompany the disease, or does it actively shape how the pathology unfolds? A new study in the journal GeroScience offers experimental evidence for the latter possibility. Researchers led by Shuai Zhao and Yanxing Chen at the Second Affiliated Hospital of Zhejiang University show that chronic cerebral hypoperfusion, when imposed at the very beginning of a tauopathy, biases where tau pathology accumulates and amplifies the inflammatory response that accompanies it. The findings suggest that vascular insufficiency may act as a disease modifier in the earliest phase of tau-related neurodegeneration, a window when interventions aimed at protecting blood flow could still alter the trajectory of the illness.

Alzheimer’s disease is characterized by two hallmark protein abnormalities: extracellular plaques of amyloid-beta and intracellular tangles of hyperphosphorylated tau. In recent years, however, the vascular side of the disease has attracted increasing attention. Population studies, including the Rotterdam Study, have linked reduced cerebral perfusion to the clinical onset of dementia, and neuroimaging work using arterial spin labeling and four-dimensional flow MRI has shown that hypoperfusion in regions such as the entorhinal cortex can precede detectable tau deposition. A scientific statement from the American Heart Association has underscored the substantial prevalence of vascular contributions to cognitive impairment and dementia in the United States. Yet most of this evidence is correlational, and the question of causality has been difficult to resolve in human studies.

Previous experimental work had already suggested that chronically starved brain tissue is fertile ground for tau. Rodent studies from several laboratories demonstrated that chronic cerebral hypoperfusion exacerbates tau hyperphosphorylation and produces behavioral deficits, with proposed mechanisms including reduced O-GlcNAcylation of tau, impaired autophagy, and compromised glymphatic clearance of waste proteins. But those experiments generally examined animals whose tau pathology was already established or arising spontaneously. Whether a sustained reduction in blood flow could influence tau pathology at its inception, when the first seeded aggregates are just beginning to form, remained unknown. The new study was designed to address precisely that gap.

The researchers used PS19 mice, a well-characterized model of tauopathy that carries the human P301S mutant tau transgene. Rather than waiting for pathology to emerge naturally, they employed a seeding approach, introducing tau seeds to initiate the pathological process, and then superimposed a model of chronic cerebral hypoperfusion by performing unilateral common carotid artery occlusion, a surgical narrowing of blood supply on one side of the brain. This design produced a powerful analytical advantage: because the hypoperfusion affected one hemisphere more than the other, the researchers could compare tau burden across the two sides of the same brain. Any ipsilateral enrichment of pathology would point to a spatially specific effect of the reduced blood flow rather than a diffuse systemic change.

The results were striking. Early hypoperfusion exacerbated tau pathology in a spatially biased pattern. In the hippocampus, the memory-forming structure that is among the first regions affected in Alzheimer’s disease, the deprived side showed enrichment of insoluble tau, the form of the protein most closely associated with aggregate formation and disease progression. In the cortex, the ipsilateral increase in tau pathology depended on the presence of tau seeds, indicating that the hypoperfusion did not create pathology de novo but instead amplified the seeded process already underway. Intriguingly, the study found no synergistic interaction between tau seeds and hypoperfusion, suggesting that the vascular insult modifies the geography and severity of tau aggregation without fundamentally changing the seed-dependent mechanism that drives it.

The white matter did not escape the vascular insult. The researchers documented myelin loss, measured through myelin basic protein, in the cortex and in the dorsal fornix, a major fiber tract that carries hippocampal outputs and has been implicated in tau pathology in human autopsy studies of Alzheimer’s disease. The involvement of the fornix is particularly notable because tau seeding has been traced along the subiculo-fornico-mamillary system in human tissue, and phospho-tau accumulation in the fornix is a recognized feature of the disease. The convergence of perfusion deficits, myelin damage, and tau vulnerability in this tract suggests a mechanistic link between vascular supply and the structural highways along which tau pathology travels.

Neuroinflammation emerged as another consequence of the combined insult. Early hypoperfusion promoted microglial activation, the resident immune cells of the brain shifting into a reactive state, and elevated levels of interleukin-1 beta, a pro-inflammatory cytokine with a documented role in tau pathology. Previous work has shown that sustained interleukin-1 beta overexpression can exacerbate tau pathology even when amyloid burden is reduced, and that microglial NF-kappaB signaling drives tau spreading and toxicity in mouse models. The hypoperfusion model also connects to a growing literature on rod-shaped microglia, a morphologically distinct subpopulation that appears in response to ischemia, injury, and neurodegeneration, and that has recently been linked to disease-associated microglial states. The new findings place the vascular trigger upstream of these inflammatory cascades in the early tauopathy setting.

The study also documented increased neuronal loss in the hippocampus of hypoperfused animals, reinforcing the idea that the vascular insult inflicts genuine damage on vulnerable circuits. Yet when the researchers assessed behavior using the Morris water maze, a standard test of spatial memory, the hypoperfusion-exposed mice showed only a marginal trend toward reduced spatial memory performance that did not reach statistical significance. This dissociation between measurable pathology and behavioral outcome is an important and honest caveat. It suggests that at the earliest stage of tauopathy, the brain may compensate for the accumulating molecular damage, and that cognitive symptoms lag behind the biological changes. For clinicians and trial designers, that lag is both a warning and an opportunity: the pathological process is underway well before function falters, which is precisely when therapeutic intervention might be most effective.

Taken together, the study provides experimental support for what vascular neurologists have long suspected from human imaging data: hypoperfusion is not a passive bystander in neurodegeneration but an active participant that can direct where pathology strikes and how strongly the inflammatory response flares. The spatially biased pattern observed here mirrors human findings that lower cerebral perfusion is associated with tau accumulation in the entorhinal cortex across the Alzheimer’s disease continuum, and that cerebrovascular disease promotes tau pathology in patient populations. If the same spatial logic operates in humans, then vascular risk factors such as hypertension, atherosclerosis, and reduced cardiac output may help determine which brain regions bear the brunt of tau aggregation, potentially explaining some of the individual variability in disease presentation and progression that genetics alone cannot account for.

The implications reach toward both early detection and therapy. Perfusion-based imaging could, in principle, identify individuals whose vulnerable brain regions are receiving marginal blood supplies before tau pathology becomes established, allowing vascular risk factor management to be prioritized in precisely those patients. Perfusion-enhancing interventions, a strategy long advocated by vascular hypothesis proponents, would gain a clearer mechanistic rationale if hypoperfusion is indeed steering early tauopathy. The work also cautions against viewing Alzheimer’s disease and vascular dementia as separate entities; the boundary between them is likely a continuum in which vascular health sets the stage upon which proteinopathies either smolder or spread. As the population ages and vascular risk factors remain widespread, understanding how blood flow shapes the earliest moments of tau pathology may prove to be one of the more tractable routes to delaying dementia, an intervention window that opens long before memory begins to slip.

Subject of Research: Effects of early chronic cerebral hypoperfusion on spatially biased tau pathology in a tau-seeded PS19 mouse model

Article Title: Early cerebral hypoperfusion promotes spatially biased tau pathology in tau-seeded PS19 mice

Article References: Early cerebral hypoperfusion promotes spatially biased tau pathology in tau-seeded PS19 mice. (n.d.). https://doi.org/10.1007/s11357-026-02587-z

Image Credits: AI Generated

DOI: 10.1007/s11357-026-02587-z

Keywords: chronic cerebral hypoperfusion, tau pathology, Alzheimer's disease, PS19 mice, neuroinflammation, microglial activation, interleukin-1 beta, myelin loss, fornix, hippocampus, vascular contributions to dementia, tau seeds